■ Kaynaklar1.Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Do distinct dyspepsia subgroups exist in the community? A population-based study. Am J Gastroenterol 2007; 102: 1983-9.
2.Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for healthcare practitioners. J Gastroenterolq Hepatol 2010; 25: 691-9.
3.Modlin I, Kidd M. GERD 2004: issues from the past and a consensus for the future. Best Pract Res Clin Gastroenterol 2004; 18(Suppl.): 55-66.
4.Kaji M, Fujiwara Y, Shiba M, et al. Prevalence of overlaps between GERD, FD and IBS and impact on healthrelated quality of life. J Gastroenterol Hepatol 2010; 25: 1151-6.
5.Noh YW, Jung HK, Kim SE, Jung SA. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III Criteria. J Neurogastroenterol Motil 2010; 16: 148-56.
6.Lee SY, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 2009; 79: 196-201.
7.Longstreth GF. Symptoms and tests for irritable bowel syndrome: diagnosing a complex disorder. Clin Gastroenterol Hepatol 2010; 8: 132-6.
8.Geeraerts B, Tack J. Functional dyspepsia: past, present, and future. J Gastroenterol 2008; 43: 251-5.
9.Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999; 45(Suppl. 2): 1-5.
10.Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
11.Quigley EM. Non-erosive reflux disease: part of the spectrum of gastrooesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001; 13(Suppl. 1): S13-8.
12.Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord 2006; 6: 72-8.
13.Fry LC, Monkemiiller K, Malfertheiner P. Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions a debate: con. Curr Treat Options Gastroenterol 2007; 10: 305-11.
14.Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8: 401-9.
15.Dickman R, Feroze H, Fass R. Gastroesophageal reflux disease and irritable bowel syndrome: a common overlap syndrome. Curr Gastroenterol Rep 2006; 8: 261-5.
16.Talley NJ. Overlapping abdominal symptoms: why do GERD and IBS often coexist? Drugs Today (Bare) 2006; 42(Suppl. B): 3-8.
17.Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Globa Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
18.Vakil N. Disease definition, clinical manifestations, epidemiology and natural history of GERD. Best Pract Res Clin Gastroenterol 2010; 24: 759-64.
19.Quigley EM, Keohane J. Dyspepsia. Curr Opin Gastroenterol 2008; 24: 692- 7.
20.Locke GR 3rd, Zinsmeister AR, Fett SL, Melton LJ 3rd, Talley NJ. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005; 17: 29-34.
21.Piessevaux H, De Winter B, Louis E, et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil 2009; 21: 378- 88.
22.Gasiorowska A, Poh CH, Fass R. Gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS) - is it one disease or an overlap of two disorders? Dig Dis Sci 2009; 54: 1829-34.
23.Neumann H, Monkemuller K, Kandulski A, Malfertheiner P. Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett’s esophagus. Dig Dis 2008; 26: 243-7.
24.Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol 2005; 19: 15-35.
25.Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-33.
26.Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of comorbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 473-82.
27.Fass R. Proton-pump inhibitor therapy in patients with gastroesophageal reflux disease: putative mechanisms of failure. Drugs 2007; 67: 1521-30.
28.Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
29.Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
30.Wang A, Liao X, Xiong L, et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol 2008; 8: 43.
31.Bolling-Sternevald E, Aro P, Ronkainen J, et al. Do gastrointestinal symptoms fluctuate in the short-term perspective? The Kalixanda study. Dig Dis 2008; 26: 256-63.
32.Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. Aliment Pharmacol Ther2008; 28: 1013-20.
33.Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671-80.
34.van Rensburg C, Berghofer P, Enns R, et al. Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. Curr Med Res Opin 2008; 24: 2009-18.
35.Schwartz MP, Samsom M, Van Berge Henegouwen GP, Smo-ut AJ. Effect of inhibition of gastric acid secretion on ant-ropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 1921-8.
36.Talley NJ, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther 2006; 23: 923-36.
37.Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010; 32: 144-58.
38.Mayberg HS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-37.
39.Wager TD, Atlas LY, Leotti LA, Rilling JK. Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience. J Neurosci 2011; 31: 439-52.
40.Talley NJ, Herrick L, Locke GR. Antidepressants in functional dyspepsia. Expert Rev Gastroenterol Hepatol 2010; 4: 5-8.
41.Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
42.Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5- HT4 agonists in irritable bowel syndrome: systematic review and metaanalysis. Am J Gastroenterol 2009; 104: 1831-43.
43.Winter JW, Heading RC. The nonerosive reflux disease-gastroesophageal reflux disease controversy. Curr Opin Gastroenterol 2008; 24: 509-15.
44.Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40: 275-85.
45.Wang C, Hunt RH. Precise role of acid in non-erosive reflux disease. Digestion 2008; 78(Suppl. 1): 31-41.
H. Mönnikes*, T. Schwan*, C. van Reıısburg*, A. Straszak§, C.
Theek , P. Sander* & R.
Lühmann*
"‘Department of Medicine, Martin-Luther-Hospital, Academic Teaching Hospital of Charité Universitatsmedizin, Berlin,
Germany.
+ Nycomed GmbH, Konstanz, Germany.
* Tygenberg Academic Hospital, Cape Town, South Africa.
§ Department of Internal Medicine, City Hospital, Siemianowice Slaskie, Poland.
’Pierrel Research, Essen, Germany. Yazışmak için:
Dr H. Mönnikes, Department of Medicine ve Institute of Neurogastroenterology, Academic Teaching Hospital Martin Luther, Charité - Universitatsmedizin Berlin, Caspar-Theyfi-Str. 27-31, 14193 Berlin, Germany.
E-mail:
moennikes@web.de Yayım bilgileri
Kabul edildiği tarih: 14 Mart 2012